DELLPHI-305

1. 07:36
   x.com

   Article updated with Day 2 of #ESMO26.
2. 07:28
   x.com

   Today, the Phase 3 results of DeLLphi-305 (@AmgenOncology @AstraZeneca) were presented by @sands_jacob at #ESMO26.
3. 05:10
   x.com

   "I fully expect this trial to establish DLL3 TCE as the dominant first line strategy in SCLC and will likely be practice changing." @TejasPatilMD on DeLLphi-305
4. 05:02
   x.com

   DeLLphi-305: OS-positive phase III.
5. 04:59
   x.com

   Impressive results of DeLLphi-305 for ES-#SCLC.
6. 04:09
   x.com

   A standing ovation: Tarlatamab + durvalumab as frontline maintenance in ES-SCLC, phase 3 DeLLphi-305:
7. 03:47
   x.com

   Breaking from the #ESMO26 Presidential Symposium! 🚨
8. 03:13
   x.com

   I always get excited by plenaries at major conferences. Today’s DeLLphi-305 results are an example of seeing the standard of care changing to better patients’ lives. Tarlatamab is
9. 02:39
   x.com

   Proud to share that the primary analysis of the phase 3 DeLLphi-305 trial was presented today at #ESMO2026 in Madrid by Dr. Jacob Sands and simultaneously published in The New Engl
10. 01:56
    x.com

    Proud to share that the primary analysis of the phase 3 DeLLphi-305 trial was presented today at #ESMO2026 in Madrid by Dr. Jacob Sands and simultaneously published in The New Engl
11. 01:54
    x.com

    ⬆️
12. 01:41
    x.com

    On Monday I told a patient with SCLC, this is the treatment plan today, but I’m hoping next week I can bring you better news from #ESMO26
13. 01:37
    x.com

    Well-deserved standing ovation! The Phase 3 DeLLphi-305 trial showed that adding tarlatamab-dlle to durvalumab maintenance therapy significantly improved OS in lung cancer (ES-SCLC
14. 01:33
    x.com

    Let’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu
15. 01:24
    x.com

    Promising results from DeLLphi-305 at #ESMO26!
16. 01:22
    x.com

    #ScienceLink #Madrid2026 #ESMO26 #DeLLphi305 #Tarlatamab #Durvalumab
17. 00:56
    x.com

    💃🍷 Eating tapas while watching the TOP #lungcancer abstracts roll in from #ESMO26 in Madrid!
18. 00:50
    x.com

    Lots of exciting developments at #ESMO26! Several important studies were also published simultaneously in major medical journals. A few highlights:
19. 00:23
    x.com

    DeLLphi-305 (phase III) #ESMO26.
20. 00:17
    x.com

    #ESMO26 Presidential 1
21. 00:07
    x.com

    #ESMO26
22. 00:05
    x.com

    #ESMO26
23. 00:04
    x.com

    Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated th
24. 00:00
    x.com

    We kick off our #ESMO26 coverage with the primary analysis of the phase 3 DeLLphi-305 trial presented by @sands_jacob

1. 23:59
   x.com

   I very much enjoyed the discussion by @StephenVLiu of DeLLphi-305 (tarlatamab + durvalumab as maintenance therapy in ES-SCLC at #ESMO26
2. 23:57
   x.com

   Standing ovation at #ESMO26! 👏
3. 23:56
   x.com

   🔥 DeLLphi-305 shook the room at #ESMO26 and what a spectacular discussion by @StephenVLiu
4. 23:54
   x.com

   Great DeLLphi-305 discussion by @StephenVLiu ; let’s not forget the drop off post induction; seems to trump lurbi; ICANS and CRS noted but manageable. #ESMO26
5. 23:54
   x.com

   DeLLphi-305 delivered the data, but Dr. Stephen Liu DeLLivered the oracle! 🔥
6. 23:53
   x.com

   Striking results from DeLLphi-305 in SCLC topped with an emotional standing ovation. Mainteinance Tarlatamab is actually more like a second induction-treatment rather than a proper
7. 23:51
   x.com

   Impressive results from phase III DeLLphi-305 at #ESMO26 @sands_jacob: Adding tarlatamab to durvalumab maintenance in ES-SCLC 1-y OS nearly 80%!!!
8. 23:51
   x.com

   DeLLphi-305 at #ESMO26, presented by Jacob Sands, got a standing ovation. An important advance in very aggressive biology. Tarlatamab + durvalumab vs durvalumab as 1L maintenance i
9. 23:51
   x.com

   Expert discussion of DeLLphi-305 by @StephenVLiu. Bringing tarlatamab to maintenance is major advance as second line tarlatamab is often “a promise we cannot keep.”
10. 23:49
    x.com

    🚨 Impressive results from #ESMO2026!
11. 23:48
    x.com

    In DeLLphi-305: The combination of Tarlatamab+ Durvalumab improves both OS (21 vs 12 months HR 0.42) and PFS in ES-SCLC. This is remarkable in such a lethal disease with high recur
12. 23:46
    x.com

    🚨 #ESMO26 | DeLLphi-305 (Phase 3) Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC after chemo-IO (N=563)
13. 23:46
    x.com

    💥Game-changer in small cell #lungcancer! #ESMO26 LBA3 DeLLphi-305: Tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC (n=563) after chemo-IO. Median OS ⬆️ 21.1 vs 12.7
14. 23:46
    x.com

    Standing ovation at #ESMO2026 for DELLPHI-305. It is heart-warming to see a meaningful survival advantage in ED-SCLC.
15. 23:45
    x.com

    #ESMO26 | DeLLphi-305
16. 23:45
    x.com

    A question about DeLLphi-305’s OS curves:
17. 23:44
    x.com

    DeLLphi-305 shows striking OS benefit with tarlatamab maintenance (HR 0.42).
18. 23:43
    x.com

    DeLLphi-305 raises a real-world challenge:
19. 23:43
    x.com

    DeLLphi-305. Immpresive curves . Additional Toxicity and cost in real world needs to be seen . Good for patients with extensive SCLC @myESMO @OncoAlert #esmo26
20. 23:42
    x.com

    Excited to see the highly anticipated DeLLphi-305 at #ESMO26. First line maintenance tarlatamab + durvalumab improves PFS and OS.
21. 23:42
    x.com

    🔥 Presidential Symposium I #ESMO26
22. 23:42
    x.com

    🔥🔥🔥 #ESMO26 DeLLphi-305 in @NEJM
23. 23:42
    x.com

    Presidential symposium 1️⃣!!
24. 23:42
    x.com

    Remarkable OS benefit in ES-SCLC! #ESMO26
25. 23:41
    x.com

    📖 A new chapter in SCLC therapy has been written by @sands_jacob
26. 23:41
    x.com

    Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12
27. 23:41
    x.com

    DeLLphi-305; ES-SCLC; nearly 2y mOS; Strong PFS signal; this is about the strongest data I’ve seen in this space. @BTOGORG #ESMO26
28. 23:40
    x.com

    📖 A new chapter in SCLC therapy has been written by @sands_jacob
29. 23:39
    x.com

    🚨🔥 ABSOLUTELY STUNNING! DeLLphi-305 at #ESMO26!
30. 23:38
    x.com

    #ESMO26 | DeLLphi-305
31. 23:38
    x.com

    DeLLphi-305 @NEJM #ESMO26
32. 23:30
    x.com

    #ESMO26: Significant improvements in overall survival in the DeLLphi-305 #ClinicalTrial with the bispecific T-cell engager #immunotherapy tarlatamab added to durvalumab could be pr
33. 23:29
    x.com

    ⭐️ #ESMO26 #LCSM
34. 23:27
    x.com

    ‼️ Impressive results from DeLLphi-305 (phase III) just out this afternoon #ESMO26.
35. 23:04
    x.com

    Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial. A new chapter in the treatment of ES-SCLC! #ESMO26
36. 22:43
    x.com

    Looking forward to the #ESMO26 Presidential Symposium! Exciting DeLLphi-305 data in ES-SCLC, presented by @JacobSandsMD, followed by what promises to be an insightful discussion fr
37. 22:40
    x.com

    #ESMO26 NEJM
38. 22:40
    x.com

    The biggest breakthrough in extensive-stage SCLC in decade
39. 22:37
    x.com

    Presented at #ESMO26:
40. 21:16
    x.com

    OncoAlert 4Sight Abstracts to be Presented at #ESMO26
41. 20:37
    x.com

    ⏰️ Coming up at #ESMO26: The first @myESMO Presidential Symposium kicks off at 4:30 PM CEST!
42. 20:10
    x.com

    WOW! BIG news for our patients with extensive-stage small cell lung cancer!
43. 19:25
    x.com

    🚨 Major SCLC results at #ESMO26!
44. 16:12
    x.com

    🔥 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 🔥
45. 15:43
    x.com

    #ESMO2026 #ESMO26 @myESMO
46. 13:45
    x.com

    DeLLphi-305 (LBA3, #ESMO26): tarlatamab + durvalumab vs durvalumab maintenance in ES-SCLC.
47. 13:08
    x.com

    #ESMO26 LBA3
48. 12:38
    x.com

    DeLLphi-305 - tarlatamab added to durvalumab after initial chemo-immunotherapy for small lung cancer essentially doubles survival. Hope for all cancers here, if the right target &a
49. 11:20
    x.com

    #ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC
50. 10:26
    x.com

    ⚡️#ESMO26 will round a very busy year for #lungcancer
51. 06:48
    x.com

    #ESMO26 | DeLLphi-305 – Phase III | Presidential Symposium-1
52. 04:31
    x.com

    🌐 #ESMO26 Día 1 | 🫁 Pulmón: SCLC y consolidación local en el foco

1. 21:42
   x.com

   SMALL CELL LUNG CANCER 1a LINEA DE MANTENIMIENTO
2. 19:31
   x.com

   The RASolute 302 brought the standing ovation. 👏
3. 19:02
   x.com

   Tomorrow at #ESMO26: the primary analysis of DeLLphi-305, tarlatamab plus durvalumab vs durvalumab alone as 1L maintenance in ES-SCLC, from our faculty member Jacob Sands (@sands_j
4. 17:21
   x.com

   🚨 #ESMO26 Lung Cancer: the 10 studies that best capture where the field is moving

1. 16:43
   x.com

   1/6 🧭 #ESMO2026 could reshape oncology competition beyond new targets.
2. 06:00
   x.com

   🫁 What lung cancer data could shape practice at #ESMO2026?

1. 21:42
   x.com

   ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH!
2. 19:11
   x.com

   Five lung cancer trials to watch at #ESMO26:
3. 18:01
   x.com

   🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁

1. 20:40
   mp.weixin.qq.com

1. 19:01
   x.com

   Tarlatamab + durvalumab as 1L maintenance in ES-SCLC: DeLLphi-305 met its OS endpoint at an interim analysis, Amgen said on 8 Sep. Our faculty member Jacob Sands (@sands_jacob) pre…

1. 05:07
   x.com

   @BalazsHalmosMD and @DylanFortman preview 14 lung cancer abstracts at #ESMO26, including DeLLphi-305 (LBA3), Krascendo 1 (LBA5), SAFFRON (LBA6), OptiTROP-Lung06 (LBA66), and PERSEE…

Heat now 422·Peak in the comparable set 481 (Oct 25 06:00)·Change over 24h in the comparable set +723%·Participants now 65

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.